Autolus Therapeutics Ltd Total Liabilities

Latest as of June 2026: $418.39 Million USD

Autolus Therapeutics Ltd total liabilities. Based on the latest financial reports, Autolus Therapeutics Ltd (AUTL) has total liabilities worth $418.39 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Autolus Therapeutics Ltd liquidity resilience to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Autolus Therapeutics Ltd (2015–2025)

Total liabilities of Autolus Therapeutics Ltd from 2015 to 2025. This chart illustrates how Autolus Therapeutics Ltd's total liabilities have evolved over time, based on quarterly financial data.

Autolus Therapeutics Ltd Competitors by Total Liabilities

The table below lists competitors of Autolus Therapeutics Ltd ranked by their total liabilities.

Company	Country	Total Liabilities
Venus Pipes & Tubes Limited NSE:VENUSPIPES	India	Rs5.68 Billion
Shenzhen Zowee Tech Co Ltd SHE:002369	China	CN¥1.99 Billion
Guangzhou Hangxin Aviation Technology Co Ltd SHE:300424	China	CN¥1.76 Billion
Zhejiang Meishuo Electric Technology Co. Ltd. A SHE:301295	China	CN¥327.67 Million
Guangdong Qunxing Toys Joint-Stock Co Ltd SHE:002575	China	CN¥83.37 Million
Ningbo Gaofa Automotive Ctrl SHG:603788	China	CN¥458.86 Million
Dayang Enterprise Holdings Bhd KLSE:5141	Malaysia	RM292.78 Million
Anhui Wantong Technology Co Ltd SHE:002331	China	CN¥1.56 Billion

Liability Composition Analysis (2015–2025)

This chart breaks down Autolus Therapeutics Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see AUTL total asset value.

Liquidity & Leverage Metrics

Autolus Therapeutics Ltd Total Liabilities Ratios Explained

Autolus Therapeutics Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric	Value	Description
Current Ratio	4.89	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	5.59	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.85	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Autolus Therapeutics Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Autolus Therapeutics Ltd (2015–2025)

The table below shows the annual total liabilities of Autolus Therapeutics Ltd from 2015 to 2025.

Year	Total Liabilities	Change
2025-12-31	$410.94 Million	+15.63%
2024-12-31	$355.40 Million	+34.67%
2023-12-31	$263.91 Million	+37.74%
2022-12-31	$191.60 Million	+107.72%
2021-12-31	$92.24 Million	+9.54%
2020-12-31	$84.20 Million	+72.93%
2019-12-31	$48.69 Million	+289.01%
2018-12-31	$12.52 Million	0.00%
2018-09-30	$12.52 Million	+106.52%
2017-12-31	$6.06 Million	+73.52%
2016-12-31	$3.49 Million	+79.28%
2015-12-31	$1.95 Million	--

About Autolus Therapeutics Ltd

NASDAQ:AUTL USA Biotechnology

Market Cap

$404.57 Million

Market Cap Rank

#13003 Global

#3206 in USA

Share Price

$1.52

Change (1 day)

-3.80%

52-Week Range

$1.21 - $2.54

All Time High

$48.01